Rasagiline


Selective irreversible MAO-B inhibitor (second-generation)

A second-generation propargyl MAO-B inhibitor lacking the amphetamine metabolites of selegiline.

Abstract

Rasagiline ((R)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine; CAS 136236-51-6; molecular formula C12H13N; molecular weight 171.24) is a second-generation irreversible MAO-B inhibitor developed at Teva and approved by the FDA in 2006 under the trade name Azilect. Structurally distinct from selegiline by the indane scaffold replacing the phenethylamine, rasagiline does not yield amphetamine-class metabolites, simplifying its drug screening profile and avoiding the subjective stimulation associated with selegiline. Approved as monotherapy in early Parkinson disease and as adjunct to levodopa in advanced disease. Plasma half-life is approximately 3 hours, but the irreversible binding produces effective enzyme inhibition for weeks. Used as a reference second-generation MAO-B inhibitor in Parkinson research.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph